Financial Performance - Underlying Revenue from customers reached $256.8 million, a 3.1% year-over-year increase[5] - Recurring Revenue accounted for $154.3 million of the Underlying Revenue[5] - Underlying Cash EBITDA was $43.8 million, resulting in a 17% Cash EBITDA margin[5] - The company ended the year with $58.7 million in cash and no debt[5] - A final FY25 dividend of $13.1 million (2.92c per share) and a special dividend of $8.0 million (1.79c per share) were distributed[5] Segment Performance - EMEA revenue was $186 million in FY25[12] - APAC revenue was $73 million in FY25[12] Future Outlook - The company expects FY26 revenues to be in line with FY25 and Cash EBITDA to be above $50 million[31] - One customer exit will impact FY26 revenue by A$10 million[37] Capital Allocation - A capital return of $73.2 million (16.3 cents per share) was paid in January 2025[28] - A special dividend of $40.0 million (8.92 cents per share) and 1H25 Dividend of $7.2 million (1.6 cents per share) was paid in April 2025[28]

YUPELRI Performance and Growth - YUPELRI net sales reached $663 million in Q2 2025, a 22% increase compared to Q2 2024[8, 19] - Excluding a one-time favorable price adjustment, YUPELRI sales still experienced mid-teens growth[19] - Hospital doses of YUPELRI grew by 31% compared to Q2 2024, achieving a new market share high of 204%[8, 19] - The YUPELRI approval in China triggered a $75 million milestone payment and potential tiered royalties of 14-20%[8, 19] Ampreloxetine Development - Enrollment in the pivotal Phase 3 CYPRESS study for Ampreloxetine is expected to be completed in late summer, with topline data anticipated approximately 6 months later[8] - Ampreloxetine targets approximately 40000 underserved patients with symptomatic nOH due to MSA[61] TRELEGY Milestones and Financials - Q2 2025 net sales of TRELEGY were approximately $11 billion, and year-to-date net sales reached approximately $20 billion, up 8% year-over-year[8, 40] - The company completed the sale of TRELEGY royalty interest for $225 million[8] - Theravance Biopharma is on pace to achieve $150 million in TRELEGY sales milestones in 2025 and 2026[40] Financial Highlights - Viatris collaboration revenue was $187 million in Q2 2025, a 31% increase year-over-year[47, 52] - Licensing revenue was $75 million in Q2 2025, driven by the YUPELRI China approval milestone[47, 52] - The company's cash and cash equivalents totaled $3388 million as of the end of Q2 2025, including the $225 million cash receipt from the TRELEGY royalty sale[52] - Non-GAAP net loss for Q2 2025 was $42 million[47, 52]

Financial Performance - Q2'25 revenue was $156 million, a 17% decrease QoQ and a 5% decrease YoY[15] - GAAP gross loss was $(124) million, while non-GAAP gross loss was $(108) million[16] - Q2'25 GAAP operating expenses were $271 million, and non-GAAP operating expenses were $470 million, including ~$4M in one-time items[16, 11] - Cash and marketable securities stood at $1076 million, excluding undrawn credit facility, equity finance program, and convertible preferred facility[17] - Free Cash Flow (FCF) was $(538) million, compared to $(443) million in Q1'25[19] Debt Management - $50 million of 2026 convertible notes were repurchased via cash & equity[8] - $135 million face amount of 2026 convertible debt remains outstanding as of August 2025, reduced from $625 million in August 2024[8, 13, 14] - The company aims to reduce 2026 convertible debt to below $100 million by year-end 2025[14] Revised Guidance - FY'25 revenue guidance lowered to $67 million to $74 million, based on sensor shipment of 20k to 23K units, down from prior outlook of 30k-33k units[20] - Non-GAAP gross loss is expected to be in the range of $(5) million to $(10) million per quarter through FY'25[20] - Non-GAAP quarterly operating expenses are expected to improve to the low-$30 million range by year-end 2025[20] - The company expects to end FY'25 with $80 million to $100 million in cash and marketable securities[21]

Financial Performance - Revenue for the second quarter of 2025 reached $700.1 million, compared to $689.9 million in the second quarter of 2024[57] - Adjusted EBITDA for the second quarter of 2025 was $82.4 million[58], while the TTM (Trailing Twelve Months) Adjusted EBITDA reached $303.3 million[20] - Net income for the second quarter of 2025 was $38.6 million, compared to $28.5 million in the second quarter of 2024[57] - The company has tightened its FY25 guidance, projecting revenue between $2.75 billion and $2.80 billion, and adjusted EBITDA between $310 million and $320 million[36] Operational Metrics - The number of early childhood education centers increased from 1,568 in June 2024 to 1,589 in June 2025[16] - Before- and after-school sites increased from 944 in June 2024 to 1,043 in June 2025, representing a 4.8% increase[16, 23] - Same-center revenue for early childhood education increased by 1% from $632.3 million to $637.7 million[16, 28] - Average weekly ECE FTEs (Full Time Enrollments) decreased slightly from 151,117 in June 2024 to 149,010 in June 2025[16] Strategic Initiatives and Market Factors - Champions expanded into 5 new districts during Q2, and Champ Camp expanded into 13 new districts, with overall growth of 99 sites in the past 12 months[13] - The new section 45F tax provision increases the annual maximum child care credit for employers from $150,000 to $500,000, and for eligible small businesses, this limit is further increased to $600,000[43] - The company's leverage ratio is 2.7x, with net debt of $807.4 million against a TTM Adjusted EBITDA of $303.3 million[31]

Q2 2025 Earnings Supplemental August 12th, 2025 Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements relate to matters such as our industry, business st ...

Financial Performance & Construction - Sky Harbour's construction is accelerating, leading to increasing revenues[20] - Sky Harbour Capital is experiencing a step up in 2025 with three new campus openings[32] - A drawdown "warehouse" bank facility is expected to provide $200 million for construction[59] - The warehouse facility is projected to fund construction of ADS2, BDL, POU1, SLC, and TTN[61] Leasing & Revenue - Stabilized campuses are enjoying higher-than-forecast revenue[70] - Potential revenue opportunity at SHER stabilization shows a 23% premium with an average expected revenue of $35.75 per rentable square foot compared to the 2022 CBRE projected $29.08, and a 38% premium with the highest expected revenue of $40.06 per rentable square foot[44] - Q2 Revenue Run Rate for SGR is $1.4 million, $5.0 million for BNA, $6.3 million for OPF, $4.0 million for SJC, and $2.9 million for DVT[48] Site Acquisition & Development - Sky Harbour reaffirms guidance of 5 new ground lease announcements by year-end[42] - The company has secured 18 airport ground leases and is targeting Tier-1 SHER locations[70] - Construction has commenced in OPF2, with completion expected by Q2 2026[70] Operational Strategy - Sky Harbour is transitioning to a centralized operating model[70] - The company is focused on maximizing revenue capture and is on course to meet its 2025 acquisitions target[74]

Financial Performance - Adjusted Distributable Earnings (DE) reached R$7576 million, a 30% increase year-over-year [14, 98] - Adjusted DE per share was R$120, up 9% year-over-year [10, 14, 97] - Fee Related Revenues totaled R$2327 million, an 85% increase year-over-year [14, 28, 31] - Fee Related Earnings (FRE) were R$652 million, a 5% increase year-over-year [14, 36] Assets Under Management (AUM) - Total AUM reached R$3041 billion, up 339% year-over-year [19] - New capital formation in 2Q'25 totaled R$36 billion [19] - Portfolio appreciation of R$81 billion occurred during the quarter [19] Segment Performance - Global IP&S AUM ended the quarter at R$230 billion [61, 62] - Credit AUM totaled R$30 billion, up 258% year-over-year [65, 67] - Private Equity AUM reached R$16 billion, up 2% year-over-year [71, 73] - Real Assets AUM totaled R$12 billion, up 14% year-over-year [80, 82]

CoreWeave Q2'25 Earnings Presentation August 12, 2025 1 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of applicable securities laws. Such statements are based on our current expectations, forecasts and assumptions and involve risks and uncertainties. These statements include, but are not limited to, statements related to our business; our strategy; our market opportunity and future growth; market trends; impact of investments in sales and marketing; an ...

Q4 FY25 Performance - Revenue reached $480.7 million[9,10,11,13], a 16% increase QoQ[8] and a 67% increase YoY[8] - Non-GAAP gross margin was 37.8%[10], compared to 35.2% in Q3 FY25[10] and 27.8% in Q4 FY24[10] - Non-GAAP operating income was $72.3 million[10], resulting in a 15.0% operating margin[10] - Non-GAAP diluted EPS was $0.88[10], compared to $0.57 in Q3 FY25[10] and $(0.13) in Q4 FY24[10] Segment Performance - Cloud & Networking revenue was $424.1 million[11] - Industrial Tech revenue was $56.6 million[11] Key Growth Drivers - Strong cloud demand, particularly from hyperscale customers, drove revenue growth[8] - Cloud module shipments exceeded the 50% QoQ growth target[8] - EML business approximately doubled compared to Q4 FY24[8] Q1 FY26 Guidance (Non-GAAP) - Revenue is projected to be between $510 million and $540 million[13] - Operating margin is expected to be between 16.0% and 17.5%[13] - Diluted EPS is projected to be between $0.95 and $1.10[13]

Financial Performance - Total revenue increased by 81% year-over-year, reaching $181.4 million in Q2 2025, compared to $100 million in Q2 2024[11] - Molecular Profiling Services revenue grew by 86% year-over-year, amounting to $162.9 million in Q2 2025, up from $87.7 million in Q2 2024[11] - Pharma R&D Services revenue increased by 49% year-over-year, reaching $18.5 million in Q2 2025, compared to $12.4 million in Q2 2024[11] - Clinical ASP improved by 52%, rising from $2,138 in Q2 2024 to $3,256 in Q2 2025[15] - Gross margin increased by 2,514 basis points year-over-year, reaching 62.7% in Q2 2025[15, 42] - Adjusted EBITDA turned positive, reaching $16.7 million in Q2 2025, compared to a loss of $50.9 million in Q2 2024[15, 34] - Free Cash Flow turned positive, reaching $5.9 million in Q2 2025, compared to a loss of $65.5 million in Q2 2024[15, 34] Operational Highlights - Clinical volume grew by 22%, with 50,032 clinical cases completed in Q2 2025[15] - The company's molecular dataset surpassed 900,000+ comprehensive tumor patient profiles, including over 529,000 Whole Exomes and 580,000 Whole Transcriptomes[15, 21] - Caris Assure ASP increased 58.7% year-over-year to $2,519 in Q2 2025[40] - MI Profile ASP increased 53.1% year-over-year to $3,379 in Q2 2025[40] Strategic Initiatives - The Partner Oncology Alliance (POA) expanded to 97 sites with over 1,100 publications[15, 23] - A landmark Caris Assure study was published, validating the single assay across the cancer care continuum[15, 26]